EST 1753 generated protein, referred to as OVA66, was assessed for immunogenicity by ELISA using 48 control sera and 113 cancer sera from patients with various malignancies including ovarian cancer (24%). This evidence concerns the gene NUDCD1 and ovarian carcinoma.